Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is
Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William
Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas’ clinical development and
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging),
Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a
Work will utilize Topas’ novel approach for antigen-specific tolerance induction Lilly has option to in-license and further develop drug candidates produced under the collaboration
Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria. Louisville, Kentucky, August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform
August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with
Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS),